Nothing Special   »   [go: up one dir, main page]

Choi et al., 1995 - Google Patents

Biodistribution of 18F-and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2α receptor-positive tumor xenografts

Choi et al., 1995

Document ID
2044360813763388866
Author
Choi C
Lang L
Lee J
Webber K
Yoo T
Chang H
Le N
Jagoda E
Paik C
Pastan I
Eckelman W
Carrasquillo J
Publication year
Publication venue
Cancer research

External Links

Snippet

We evaluated the biodistribution, pharmacokinetics, and generation of catabolites of an 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragment (dsFv) in tumor-bearing nude mice. This dsFv is genetically engineered from a murine monoclonal antibody that …
Continue reading at aacrjournals.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components

Similar Documents

Publication Publication Date Title
Choi et al. Biodistribution of 18F-and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2α receptor-positive tumor xenografts
Adams et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erb B-2 single-chain Fv
Vaidyanathan et al. Improved synthesis of N-succinimidyl 4-[18F] fluorobenzoate and its application to the labeling of a monoclonal antibody fragment
Kukis et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates
Kobayashi et al. L-lysine effectively blocks renal uptake of 125I-or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment
Schott et al. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules
JPH10508832A (en) Modified radioactive antibody fragments that reduce renal uptake
US20090214423A1 (en) Selective targeting of tumor vasculature using radiolabelled antibody molecules
EP1483297B1 (en) Antibodies derived from anti ed-b l19 and targeting tumor vasculature
Khawli et al. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1,-2, and-3 monoclonal antibodies after chemical modification with biotin
Khawli et al. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors
Khawli et al. Improved tumor localization and radioimaging with chemically modified monoclonal antibodies
Garg et al. Catabolism of radioiodinated murine monoclonal antibody F (ab') 2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods
Kim et al. Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents
Alauddin et al. An improved method of direct labeling monoclonal antibodies with 99mTc
Khawli et al. Tumor targeting properties of indium-111 labeled genetically engineered Fab′ and F (ab′) 2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody
Pavlinkova et al. Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct
Carrasquillo et al. Aminosyn II effectively blocks renal uptake of 18F-labeled anti-tac disulfide-stabilized Fv
Adams et al. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated iv administration
Yoo et al. Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment
Kobayashi et al. Similarities in the biodistribution of iodine-labeled anti-Tac single-chain disulfide-stabilized Fv fragment and anti-Tac disulfide-stabilized Fv fragment
del Rosario et al. Biotinylated iodo-polylysine for pretargeted radiation delivery
Stalteri et al. A cross-linked monoclonal antibody fragment for improved tumor targeting
Webber et al. Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors
Kobayashi et al. Improved Biodistribution of 125I-labeled Anti-Tac Disulfide-stabilized Fv Fragment by Blocking Its Binding to the α Subunit of the Interleukin 2 Receptor in the Circulation with Preinjected Humanized Anti-Tac IgG